Soleno Therapeutics (SLNO) Expected to Announce Earnings on Wednesday

Soleno Therapeutics (NASDAQ:SLNO) is expected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Soleno Therapeutics to post earnings of $0.59 per share and revenue of $88.5470 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Soleno Therapeutics Price Performance

Shares of NASDAQ:SLNO opened at $39.36 on Monday. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $43.59 and its two-hundred day simple moving average is $54.64. Soleno Therapeutics has a 1-year low of $36.67 and a 1-year high of $90.32. The stock has a market cap of $2.11 billion, a PE ratio of -21.39 and a beta of -3.16.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $120.00 target price (up previously from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research note on Tuesday, January 13th. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Finally, Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.62.

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Soleno Therapeutics by 50.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after acquiring an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Soleno Therapeutics by 48.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after acquiring an additional 13,211 shares during the last quarter. Creative Planning bought a new stake in Soleno Therapeutics in the 2nd quarter valued at about $338,000. Finally, Prudential Financial Inc. purchased a new stake in Soleno Therapeutics during the second quarter valued at about $413,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.